Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Apple Turns 50: From Garage Startup to AI Crossroads 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
 and Lead Plaintiff Deadline: March 6, 2017 - EconoTimes)
NEW YORK, Jan. 06, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Endologix Inc. (“Endologix” or the “Company”) (NASDAQ:ELGX) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Endologix securities August 2, 2016 through November 16, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/elgx.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the necessary clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) consequently, the Company’s public statements were materially false and misleading at all relevant times.
On November 16, 2016, Endologix revealed that the FDA requested the Company to provide them with follow up data for two years for patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Following this news, Endologix stock dropped $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/elgx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
